$RGC ’s four-year lookout RGC a bioscience an
Post# of 24950
(Total Views: 171)
Posted On: 12/28/2022 7:42:17 AM
$RGC ’s four-year lookout
RGC a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment specifically ADHD and ASD, and infectious diseases targeting people’s immune system ie. COVID.
Mr Yat-Gai Au, a practitioner of TCM and also company CEO, since IPO day has bought over $5 million of ordinary shares and has not sold any shares despite the having seen the stock price rose staggeringly. The company is currently in the business for the long run and will continue to be vested in its business model of developing treatments for AHDH and ASD as treatment trials are ongoing.
***Upcoming results in follow-on study of ASD/ADHD treatment formula***
Regencell Bioscience is expected to report results of a follow-on study for its ASD/ADHD treatment. Currently, the Company is working towards the production of an effective standardized formula for commercialization purposes.
The formula is based on the “Sik-Kee Au TCM Brain Theory” that ASD and ADHD stem from inadequate blood flow and creation of neurotransmitters in the developing brain.
This treatment hypothesis is complementary to the western medicine view that ASD and ADHD are present at birth and arise from developmental differences in brain function.
Regencell Bioscience’s first clinical trial was designed to establish benchmarks for treatment, dosing, adverse effects (AEs) and measuring patients’ response in a systematic and repeatable way, while evaluating the effectiveness of a customized TCM formula.
As a customized formula is designed to suit each patient’s symptoms, the ability for it to be produced in large quantities is limited as compared to a standardized formula.
Regencell is currently evaluating and assessing the effectiveness of a standardized TCM formula in reducing ADHD and ASD symptoms in children through a holistic approach within 3 months of treatment, in its second efficacy trial.
**RGC’s Path to registration and commercialization**
Regencell Bioscience has a **four-year timeframe** to commercialize its standardized formulations and gain proprietary Chinese medicine (pCm) registration in Hong Kong. The Company has a number of tasks ahead:
- Completing its second clinical trial for ASD/ADHD and COVID, and evaluating results.
- Conducting additional clinical trials to support its proprietary formulae in ASD/ADHD and other applications.
- Obtaining patents and other forms of IP protection in Hong Kong and other markets.
- Establishing manufacturing capability and supply chain that will meet registration requirements.
- Assembling and filing documentation for pCm approval.
- Build out its marketing and distribution strategy and infrastructure.
RGC a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment specifically ADHD and ASD, and infectious diseases targeting people’s immune system ie. COVID.
Mr Yat-Gai Au, a practitioner of TCM and also company CEO, since IPO day has bought over $5 million of ordinary shares and has not sold any shares despite the having seen the stock price rose staggeringly. The company is currently in the business for the long run and will continue to be vested in its business model of developing treatments for AHDH and ASD as treatment trials are ongoing.
***Upcoming results in follow-on study of ASD/ADHD treatment formula***
Regencell Bioscience is expected to report results of a follow-on study for its ASD/ADHD treatment. Currently, the Company is working towards the production of an effective standardized formula for commercialization purposes.
The formula is based on the “Sik-Kee Au TCM Brain Theory” that ASD and ADHD stem from inadequate blood flow and creation of neurotransmitters in the developing brain.
This treatment hypothesis is complementary to the western medicine view that ASD and ADHD are present at birth and arise from developmental differences in brain function.
Regencell Bioscience’s first clinical trial was designed to establish benchmarks for treatment, dosing, adverse effects (AEs) and measuring patients’ response in a systematic and repeatable way, while evaluating the effectiveness of a customized TCM formula.
As a customized formula is designed to suit each patient’s symptoms, the ability for it to be produced in large quantities is limited as compared to a standardized formula.
Regencell is currently evaluating and assessing the effectiveness of a standardized TCM formula in reducing ADHD and ASD symptoms in children through a holistic approach within 3 months of treatment, in its second efficacy trial.
**RGC’s Path to registration and commercialization**
Regencell Bioscience has a **four-year timeframe** to commercialize its standardized formulations and gain proprietary Chinese medicine (pCm) registration in Hong Kong. The Company has a number of tasks ahead:
- Completing its second clinical trial for ASD/ADHD and COVID, and evaluating results.
- Conducting additional clinical trials to support its proprietary formulae in ASD/ADHD and other applications.
- Obtaining patents and other forms of IP protection in Hong Kong and other markets.
- Establishing manufacturing capability and supply chain that will meet registration requirements.
- Assembling and filing documentation for pCm approval.
- Build out its marketing and distribution strategy and infrastructure.
(0)
(0)Scroll down for more posts ▼